Marvel Biosciences Corp. MRVL.V
TSX
| 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | 04/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 195.40K | 181.30K | 140.80K | 173.30K | 175.80K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 248.00K | 185.10K | 182.20K | 355.70K | 176.10K |
| Operating Income | -248.00K | -185.10K | -182.20K | -355.70K | -176.10K |
| Income Before Tax | 318.50K | -213.20K | -246.60K | -866.30K | -181.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 318.50K | -213.20K | -246.60K | -866.30K | -181.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 318.50K | -213.20K | -246.60K | -866.30K | -181.10K |
| EBIT | -248.00K | -185.10K | -182.20K | -355.70K | -176.10K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.01 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | 0.01 | 0.00 | 0.00 | -0.02 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 61.56M | 57.99M | 55.57M | 52.97M | 44.79M |
| Average Diluted Shares Outstanding | 61.56M | 57.99M | 55.57M | 52.97M | 44.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |